Adipokine genes and prostate cancer risk

Authors

  • Steven C. Moore,

    Corresponding author
    1. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD
    2. Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT
    • 6120 Executive Boulevard, Bethesda, MD 20892, USA
    Search for more papers by this author
    • Fax: 301-496-6829.

  • Michael F. Leitzmann,

    1. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD
    2. Institute of Epidemiology and Preventive Medicine, University Hospital Regensburg, Germany
    Search for more papers by this author
  • Demetrius Albanes,

    1. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD
    Search for more papers by this author
  • Stephanie J. Weinstein,

    1. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD
    Search for more papers by this author
  • Kirk Snyder,

    1. Information Management Services, Silver Spring, MD
    Search for more papers by this author
  • Jarmo Virtamo,

    1. Department of Health Promotion and Chronic Disease Prevention, National Public Health Institute, Helsinki, Finland
    Search for more papers by this author
  • Jiyoung Ahn,

    1. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD
    Search for more papers by this author
  • Susan T. Mayne,

    1. Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT
    Search for more papers by this author
  • Herbert Yu,

    1. Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT
    Search for more papers by this author
  • Ulrike Peters,

    1. Cancer Prevention Program, Public Health Science, Fred Hutchinson Cancer Research Center and Department of Epidemiology, School of Public Health, University of Washington, Seattle, WA
    Search for more papers by this author
  • Marc J. Gunter

    1. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD
    2. Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY
    Search for more papers by this author

Abstract

Adiposity and adipocyte-derived cytokines have been implicated in prostate carcinogenesis. However, the relationship of adipokine gene variants with prostate cancer risk has not been thoroughly investigated. We therefore examined common variants of the IL6, LEP, LEPR, TNF and ADIPOQ genes in relation to prostate cancer in a case-control study nested within a large cohort of Finnish men. The study sample consisted of 1,053 cases of prostate cancer, diagnosed over an average 11 years of follow up, and 1,053 controls matched to the cases on age, intervention group and date of baseline blood draw. Logistic regression was used to model the relative odds of prostate cancer. We also examined genotypes in relation to serum insulin, IGF-1 and IGF-1:IGFBP-3 among 196 controls. Variant alleles at three loci (−14858A>G, −13973A>C, −13736C>A) in a potential regulatory region of the LEP gene conferred a statistically significant 20% reduced risk of prostate cancer. For example, at the −14858A>G locus, heterozygotes and homozygotes for the A allele had an odds ratio (OR) of prostate cancer of 0.76 [95% confidence interval (CI) 0.62, 0.93] and 0.79 (95% CI 0.60, 1.04), respectively. At 13288G>A, relative to the GG genotype, the AA genotype was associated with a suggestive increased risk of prostate cancer (OR = 1.29; 95% CI 0.99,1.67; ptrend = 0.05). Polymorphisms in the IL6, LEPR, TNF and ADIPOQ genes were not associated with prostate cancer. Allelic variants in the LEP gene are related to prostate cancer risk, supporting a role for leptin in prostate carcinogenesis. © 2008 Wiley-Liss, Inc.

Ancillary